Ribonucleotide reductase subunit M1 blocks glucose catabolism via phosphorylation of pyruvate kinase M2 in human esophageal squamous cell cancer  

作　　者：Jian Yang Lingxiao Wang Hui Sun Zhenxiang Zhao Yanchuan Ma Zhen Hu Liqin Zhai Yonggang Wang 

机构地区：[1]Translational Medicine Research Center,Shanxi Medical University,Taiyuan,Shanxi030001,China [2]Department of Cell Biology and Genetics,Shanxi Medical University,Taiyuan,Shanxi 030001,China [3]Key Laboratory of Cellular Physiology of the Ministry of Education,Shanxi Medical University,Taiyuan,Shanxi 030001,China [4]Department of Colorectal Surgery,The Fifth Clinical Medical College of Shanxi Medical University,Taiyuan,Shanxi 030012,China [5]Science&Technology Information and Strategy Research Center of Shanxi,Taiyuan,Shanxi 030006,China [6]Department of Pathology,Shanxi Provincial People's Hospital,Taiyuan,Shanxi 030012,China [7]Department of Anatomy,College of Basic Medicine,Shanxi Medical University,Taiyuan,Shanxi 030001,China

出　　处：《Genes & Diseases》2024年第3期69-71,共3页基因与疾病（英文）

基　　金：supported by the National Natural Science Foundation of China(No.82103175);the Natural Science Foundation of Shanxi Province,China(No.201901D111432,20210302123316,202103021224379).

摘　　要：Esophageal squamous cell cancer(EScC)is one of the malignant tumors with high morbidity and mortality all over the world.^(1) In recent years,combined chemotherapy has gradually been the effective treatment method for EscC patients.Therefore,it is imperative to explore potential therapeutic targets for the treatment of EsCC.We previously reported a high-frequency amplification of pyrimidine metabolic pathway-related genes in EsCC tissues.

关 键 词：SQUAMOUS ESOPHAGEAL cancer 

分 类 号：R735.1[医药卫生—肿瘤]